673 results on '"Andersen, Mads Hald"'
Search Results
52. Anti-regulatory T cells
53. Tumor-Produced Immune Regulating Factors
54. Cancer Vaccines and the Potential Benefit of Combination with Standard Cancer Therapies
55. Tumor microenvironment antigens
56. CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment
57. Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
58. Peripheral memory T cells specific for Arginase-1
59. Cancer and autoimmunity
60. PD-L1-specific T cells
61. Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
62. IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
63. Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
64. Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology
65. Bioinformatics for cancer immunotherapy target discovery
66. A Potential Role of Indoleamine 2,3-Dioxygenase-Specific T cells in "Leishmania" Vaccination
67. Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
68. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer
69. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
70. 778 Modulating tumor microenvironment with arginase-1 specific T cells
71. Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
72. Self-reactive T cells: suppressing the suppressors
73. Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
74. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile
75. The Targeting of Indoleamine 2,3 Dioxygenase -Mediated Immune Escape in Cancer
76. Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709)
77. Immune-suppressive properties of the tumor microenvironment
78. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
79. The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
80. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
81. Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients
82. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines
83. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
84. Identification of heme oxygenase-1--specific regulatory [CD8.sup.+] T cells in cancer patients
85. RhoC a new target for therapeutic vaccination against metastatic cancer
86. Cancer treatment: the combination of vaccination with other therapies
87. Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
88. Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
89. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient
90. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes
91. Survivin
92. Regulators of apoptosis: suitable targets for immune therapy of cancer
93. Spontaneous T-cell responses against peptides derived from the Taxol resistance–associated gene-3 (TRAG-3) protein in cancer patients
94. Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
95. Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens
96. Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade
97. Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
98. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
99. Efficacy and safety of IO103 a novel anti PD-L1 vaccine in basal cell carcinoma.
100. MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.